Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Thyroid cancer
Larotrectinib Delivers 79% ORR and 71% Six-Year OS in NTRK-Fusion Differentiated Thyroid Cancer
Larotrectinib, a highly selective CNS-penetrant TRK inhibitor, was pooled across three trials (n=31; NCT02576431, NCT02122913, NCT02637687). In advanced TRK-fusion thyroid carcinoma, adults received 100 mg BID. Among…
NCT02576431 - Trial result
Bladder and urothelial cancer
Avelumab + Docetaxel Scores 52% ORR in Platinum-Refractory or -Ineligible mUrothelial Carcinoma
In the single-arm Phase 1b AVETAX trial (NCT03575013), 21 patients with metastatic urothelial carcinoma who were either platinum-refractory (n=8) or cisplatin-ineligible (n=13) received docetaxel plus avelumab,…
NCT03575013 - Trial result
Acute myeloid leukemia and MDS
SENTI-202 Logic-Gated CD33/FLT3 CAR-NK Cells Show 44% MRD-Negative CR in First-in-Human AML Study
SENTI-202 is a ready-made cell therapy that uses natural killer (NK) cells engineered to target cancer in a smart and precise way. It includes an “OR-gate” sensor that activates the cells when they detect either of…
- Trial result
Sarcoma and GIST
Varegacestat (γ-Secretase Inhibitor) Shrinks Desmoid Tumors in 46–78% of Patients Across All Subgroups
In the RINGSIDE Phase 2 open label trial (NCT04871282), 42 adults with progressing desmoid tumors received the oral γ-Secretase Inhibitor, varegacestat 1.2 mg QD, 2 mg or 4 mg. (2 days on/5 off); median follow-up 23…
NCT04871282 - New trial
Multiple solid tumors
Phase 1 Study of XB628 Targeting NKG2A and PD-L1 in Advanced Solid Tumors
Exelixis is conducting a first-in-human, open-label, dose-escalation trial of XB628—a bispecific antibody that engages NK cells by targeting NKG2A and PD-L1—in patients with recurrent advanced or metastatic solid tumors.
NCT06952010 - New trial
Multiple solid tumors
Phase 1 FIH Study of ABBV-324 (Undisclosed ADC) in HCC and Squamous NSCLC
AbbVie is evaluating ABBV-324—an investigational antibody–drug conjugate with an undisclosed target—in patients with advanced hepatocellular carcinoma and squamous-cell non–small cell lung cancer through dose…
NCT06858813 - New trial
Multiple solid tumors
Phase I/IIa FAP-Targeted Alpha-Particle Therapy in FAP-Positive Solid Tumors
Perspective Therapeutics is evaluating both imaging and therapeutic peptide-based radiopharmaceuticals ([203Pb]Pb-PSV359 for imaging and [212Pb]Pb-PSV359 for alpha-particle treatment) across dose escalation and…
NCT06710756 - New trial
Multiple solid tumors
Pilot PET Imaging Study of [89Zr]DFO-starPEG for EPR in Solid Tumors
This first-in-human pilot study assesses the novel PET radiotracer [89Zr]DFO-starPEG—designed to visualize the enhanced permeability and retention (EPR) effect—for its ability to capture whole-body tracer uptake at…
NCT06894745 - New trial
Multiple solid tumors
ASP-1929 Photoimmunotherapy with Anti-PD1 in Advanced EGFR-Expressing Squamous Cancers
Rakuten Medical is conducting an open-label study evaluating ASP-1929—a cetuximab-based, EGFR-targeted photoactivatable agent—in combination with PD-1 inhibitors (pembrolizumab or cemiplimab) across…
NCT04305795 - New trial
Multiple solid tumors
Phase II Trial of Optimal Margins in Brain Metastases Radiosurgery
UAB is evaluating differential planning target volume margins (0 mm vs 2 mm) in single isocenter radiosurgery for brain metastases ≤4 cm to optimize dosing based on tumor size.
NCT06857006 - New trial
Multiple solid tumors
Phase II Trial of VMAT CSI in Leptomeningeal Metastasis
NYU Langone Health is evaluating linac-based Volumetric Modulated Arc Therapy (VMAT) craniospinal irradiation (CSI) in solid tumor patients with leptomeningeal metastasis to improve central nervous system…
NCT06984523 - New trial
Lung cancer
Phase 3 Trial of N-803 + Tislelizumab + Docetaxel in NSCLC with EGFR Mutations
ImmunityBio is evaluating an experimental combination of N-803—a two human IL-15 variant fusion protein that enhances immunostimulation—plus tislelizumab (a PD-1 inhibitor) and docetaxel versus docetaxel monotherapy…
NCT06745908 - New trial
Lung cancer
Phase Ib/II Trial of BNT324 (B7-H3 ADC) + BNT327 (PD-L1/VEGF Bispecific) in Advanced Lung Cancer
BioNTech SE is evaluating the combination of BNT324—a B7-H3 antibody-drug conjugate delivering an undisclosed toxin—with BNT327, a VEGFA directed antibody that also targets PD-L1 and VEGF, across multiple cohorts in…
NCT06892548 - New trial
Lung cancer
Phase 1b Study of Tarlatamab (DLL3/CD3) & YL201 (B7-H3 ADC) ± anti-PD-L1 in Extensive Stage SCLC
Amgen is evaluating the safety, tolerability, and efficacy of combining tarlatamab—a bispecific mAb targeting DLL3 and CD3—with YL201, a B7-H3 directed ADC, with or without PD-L1 inhibitors in extensive stage SCLC…
NCT06898957 - New trial
Prostate cancer
Phase 3 Study of Ifinatamab Deruxtecan (B7-H3 ADC) Versus Docetaxel in mCRPC
Merck is sponsoring this open-label study comparing ifinatamab deruxtecan—a B7-H3–directed antibody-drug conjugate with a Topo1 inhibitor payload—with standard docetaxel plus prednisone in patients with mCRPC…
NCT06925737 - New trial
Prostate cancer
Micro-US vs MRI in Active Surveillance for Detecting ≥GG2 Prostate Cancer
University of Alberta is conducting the MUSIC-AS trial to compare micro-ultrasound–guided biopsies (using the UTZ Imaging System) with MRI-guided methods in active surveillance of Gleason Grade Group 1 prostate…
NCT05558241 - New trial
Prostate cancer
Trial of 177Lu-PSMA-617 (Pluvicto) in PSMA-Positive mCRPC with Super Scan Bone Metastases
This study evaluates the safety, tolerability, and optimal dosing of Pluvicto—a PSMA-directed beta emitter radiation conjugate—in men with progressive metastatic castration-resistant prostate cancer (mCRPC)…
NCT06972628 - New trial
Pancreatic cancer
Phase I Trial of Adaptive Radiation Therapy for Pancreatic Cancer with CT Marker Guidance
Fox Chase Cancer Center is assessing the safety and efficacy of Adaptive Radiation Therapy in patients with locally advanced, unresectable pancreatic cancer. The study uses CT-based planning with 1–3 markers placed…
NCT06984562 - New trial
Pancreatic cancer
Phase 1 Trial of Cosibelimab and Balixafortide Targeting PD-L1 and CXCR4 in Metastatic PDAC
An open-label phase 1 study at Cedars-Sinai is evaluating the safety and tolerability of cosibelimab—a PD-L1 directed monoclonal antibody—and balixafortide, a CXCR4 inhibitor, in metastatic pancreatic ductal…
NCT06981806 - New trial
Breast cancer
Phase 1/2 Trial of Sacituzumab Govitecan in TROP2-Positive Triple-Negative Breast Cancer
Gilead Sciences is evaluating sacituzumab govitecan-hziy—a TROP2-directed antibody-drug conjugate delivering SN38—in advanced TNBC using alternate dosing schedules to assess safety, tolerability, ORR, and PFS.
NCT06926920 - New trial
Breast cancer
Phase II ctDNA-Guided Elacestrant Trial in ER+ HER2- Breast Cancer
Yale University is conducting a single-arm phase II study to evaluate elacestrant—a small molecule estrogen receptor inhibitor—at an FDA-approved dose of 345 mg daily for adjuvant treatment in ER+ HER2- breast cancer…
NCT06923527 - New trial
Kidney cancer
LASER - Phase 2 Trial of 177Lu-PSMA-617 in PSMA-Positive ccRCC
Dana-Farber is evaluating 177Lu-PSMA-617—a radioligand therapy delivering beta radiation via lutetium-177 vipivotide tetraxetan—as a systemic treatment in PSMA-positive advanced/metastatic clear cell renal cell…
NCT06964958 - New trial
Brain and CNS tumors
Phase 1 Trial of AZD1390 (ATM Inhibitor) with Radiation in Pediatric High-Grade Glioma
Children's Oncology Group is evaluating AZD1390—a small molecule ATM inhibitor that disrupts cancer cell repair processes—administered with focal radiation in pediatric patients with high grade glioma (including…
NCT06894979 - New trial
Multiple myeloma
Phase II Study of Talquetamab (GPRC5D/CD3 Bispecific) in Post-Transplant Multiple Myeloma Maintenance
Stanford University is launching an open-label, non-randomized Phase II study evaluating talquetamab—a bispecific antibody targeting GPRC5D and CD3—as monotherapy in cycle 1 and in combination with lenalidomide from…
NCT06461988 - New trial
Other blood cancers and transplant
Phase 1/2 Trial of ARD103 CLL-1 CAR-T in R/R AML/MDS
ARCE Therapeutics is conducting an open-label, multicenter trial to assess ARD103—a CLL-1 directed CAR-T—administered alongside cyclophosphamide and fludarabine in relapsed/refractory AML or MDS patients.
NCT06680752 - New trial
Other blood cancers and transplant
Phase 2 Trial of Pacritinib for R/R Waldenström Macroglobulinemia (JAK2/FLT3 Inhibitor)
This Phase 2 study evaluates pacritinib—a JAK2 and FLT3 inhibitor—for relapsed/refractory Waldenström macroglobulinemia patients (including those ineligible for BTK inhibitors) with a treatment plan that includes…
NCT06986174 - Trial result
Multiple solid tumors
Pembrolizumab (PD-1) neoadjuvant delivers 80% 3-yr EFS in dMMR/MSI-H tumors; ctDNA pinpoints relapse risk
Phase II NCT04082572 enrolled 35 patients with locally advanced dMMR/MSI-H solid tumors who received neoadjuvant pembrolizumab; at 3 years, event-free and overall survival reached 80% (95% CI 66-93) and 94% (86-100).…
NCT04082572 - Trial result
Multiple solid tumors
BMS-986504 (PRMT5-MTA inhibitor) posts 23% ORR and 10.5-mo responses in MTAP-deleted solid tumors
In the first-in-human Phase I/II CA240-0007 study (ASCO #3011), 152 heavily pre-treated patients with homozygous MTAP-deleted advanced cancers—most commonly PDAC (27%), NSCLC (22%), cholangiocarcinoma and…
- Trial result
Multiple solid tumors
DYP688 ADC Delivers Direct Gq/11 Inhibition with a 21.8% Response Rate in Metastatic Uveal Melanoma and other GNAQ/11 Mutant Melanomas
In the first-in-human Phase I dose-escalation study (NCT05415072, n = 66), DYP688 achieved a confirmed ORR of 21.8% (1 CR) in 55 evaluable patients with metastatic uveal or other GNAQ/11-mutant melanoma treated at ≥8…
NCT05415072 - Trial result
Multiple solid tumors
Larotrectinib, TRK Inhibitor, Achieves 77% Response in Treatment-Naïve (First-Line) TRK Fusion Cancers
In 101 patients across three trials including pediatric patients, larotrectinib, the TRK inhibitor, yielded a 77% overall response rate with median PFS of 61 months. Overall survival was not reached. Most…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.